

John K Ramage

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9491160/john-k-ramage-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|--------------------|--------------------------|----------------|-----------------|
| 135 papers | 8,719 citations | 48 h-index | 92 g-index |
| 149 ext. papers | 10,292 ext. citations | 7.2 avg, IF | 5.31 L-index |

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 135 | Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module).. <i>Journal of Neuroendocrinology</i> , 2022 , e13097 | 3.8 | 0 |
| 134 | Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours.. <i>Journal of Neuroendocrinology</i> , 2022 , e13096 | 3.8 | 1 |
| 133 | Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire.. <i>Journal of Cancer Survivorship</i> , 2022 , 1 | 5.1 | 0 |
| 132 | ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors.. <i>Journal of Neuroendocrinology</i> , 2022 , e13105 | 3.8 | 4 |
| 131 | Efficacy and safety of Lu-DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022 , 1 | 8.8 | 1 |
| 130 | Evaluating cost-effectiveness in the management of neuroendocrine neoplasms. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021 , 22, 647-663 | 10.5 | 0 |
| 129 | Nodal metastases in small rectal neuroendocrine tumours. <i>Colorectal Disease</i> , 2021 , 23, 3173 | 2.1 | 0 |
| 128 | Calcitonin-secreting neuroendocrine neoplasms of the lung: a systematic review and narrative synthesis. <i>Endocrine Connections</i> , 2021 , 10, 447-461 | 3.5 | 0 |
| 127 | Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. <i>Lancet Oncology, The</i> , 2021 , 22, 690-701 | 21.7 | 100 |
| 126 | Efficacy and safety of 177Lu-DOTATATE in patients (pts) with advanced pancreatic neuroendocrine tumors (pNETs): Data from the NETTER-R international, retrospective registry.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4116-4116 | 2.2 | 1 |
| 125 | The Impact of Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours. <i>Frontiers in Endocrinology</i> , 2021 , 12, 654975 | 5.7 | 1 |
| 124 | X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. <i>Gastroenterology</i> , 2021 , 160, 2483-2495.e26 | 13.3 | 9 |
| 123 | Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply. <i>Lancet Oncology, The</i> , 2021 , 22, e288-e289 | 21.7 | 1 |
| 122 | Evaluating the Thresholds for Clinical Importance of the EORTC QLQ-C15-PAL in Patients Receiving Palliative Treatment. <i>Journal of Palliative Medicine</i> , 2021 , 24, 397-404 | 2.2 | 3 |
| 121 | Finding the needle in the haystack: the diagnostic accuracy of the faecal immunochemical test for colorectal cancer in younger symptomatic patients. <i>Colorectal Disease</i> , 2021 , 23, 2539-2549 | 2.1 | 0 |
| 120 | Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome. <i>Journal of Oncology</i> , 2020 , 2020, 8341426 | 4.5 | 21 |
| 119 | Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors. <i>Anti-Cancer Drugs</i> , 2020 , 31, 216-222 | 2.4 | 3 |

| | | | |
|-----|--|-----|----|
| 118 | International validation of the EORTC CAT Core: a new adaptive instrument for measuring core quality of life domains in cancer. <i>Quality of Life Research</i> , 2020 , 29, 1405-1417 | 3.7 | 10 |
| 117 | Health-related quality of life in neuroendocrine neoplasia: a critical review. <i>Endocrine-Related Cancer</i> , 2020 , 27, R267-R280 | 5.7 | 4 |
| 116 | Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review. <i>World Journal of Gastroenterology</i> , 2020 , 26, 3686-3711 | 5.6 | 6 |
| 115 | Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. <i>Journal of Clinical Epidemiology</i> , 2020 , 118, 1-8 | 5.7 | 65 |
| 114 | Timing of peptide receptor radiotargeted therapy in relation to cardiac valve surgery for carcinoid heart disease in patients with neuroendocrine metastases and cardiac syndrome. A single-centre study from a centre of excellence. <i>Nuclear Medicine Communications</i> , 2020 , 41, 575-581 | 1.6 | 2 |
| 113 | Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) \geq 1 cm: Study Protocol for a Prospective Observational Study. <i>Frontiers in Medicine</i> , 2020 , 7, 598438 | 4.9 | 7 |
| 112 | Thresholds for clinical importance were defined for the European Organisation for Research and Treatment of Cancer Computer Adaptive Testing Core-an adaptive measure of core quality of life domains in oncology clinical practice and research. <i>Journal of Clinical Epidemiology</i> , 2020 , 117, 117-125 | 5.7 | 7 |
| 111 | Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013-2015. <i>British Journal of Cancer</i> , 2019 , 121, 966-972 | 8.7 | 21 |
| 110 | Affective and enjoyment responses to 12 weeks of high intensity interval training and moderate continuous training in adults with Crohn's disease. <i>PLoS ONE</i> , 2019 , 14, e0222060 | 3.7 | 4 |
| 109 | Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial). <i>Neuroendocrinology</i> , 2019 , 108, 317-327 | 5.6 | 9 |
| 108 | High-intensity interval training and moderate-intensity continuous training in adults with Crohn's disease: a pilot randomised controlled trial. <i>BMC Gastroenterology</i> , 2019 , 19, 19 | 3 | 17 |
| 107 | Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. <i>Journal of Patient-Reported Outcomes</i> , 2019 , 3, 64 | 2.6 | 1 |
| 106 | Nutritional and vitamin status in patients with neuroendocrine neoplasms. <i>World Journal of Gastroenterology</i> , 2019 , 25, 1171-1184 | 5.6 | 16 |
| 105 | Colorectal Neuroendocrine Neoplasms: Areas of Unmet Need. <i>Neuroendocrinology</i> , 2019 , 108, 45-53 | 5.6 | 11 |
| 104 | Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors. <i>BMC Cancer</i> , 2019 , 19, 66 | 4.8 | 20 |
| 103 | Ileocolonic neuroendocrine tumours identified in the English bowel cancer screening programme. <i>Colorectal Disease</i> , 2018 , 20, O85-O91 | 2.1 | 6 |
| 102 | Tumour Staging: Ileum 2018 , 197-206 | | |
| 101 | Presenting Symptoms and Delay in Diagnosis of Gastrointestinal and Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2018 , 107, 42-49 | 5.6 | 15 |

| | | | |
|-----|---|------|-----|
| 100 | A cross-cultural convergent parallel mixed methods study of what makes a cancer-related symptom or functional health problem clinically important. <i>Psycho-Oncology</i> , 2018 , 27, 548-555 | 3.9 | 12 |
| 99 | Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire. <i>Health and Quality of Life Outcomes</i> , 2018 , 16, 114 | 3 | 81 |
| 98 | Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 626-634 | 18.8 | 60 |
| 97 | Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2018 , 22, 1-326 | 4.4 | 16 |
| 96 | Phase III study of the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) and specific complementary outpatient module (EORTC OUT-PATSAT7). <i>European Journal of Cancer Care</i> , 2018 , 27, e12786 | 2.4 | 13 |
| 95 | Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR. <i>Clinical Therapeutics</i> , 2018 , 40, 2006-2020.e2 | 3.5 | 18 |
| 94 | Delays and routes to diagnosis of neuroendocrine tumours. <i>BMC Cancer</i> , 2018 , 18, 1122 | 4.8 | 23 |
| 93 | Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors. <i>Seminars in Oncology</i> , 2018 , 45, 236-248 | 5.5 | 37 |
| 92 | Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 951-960 | 6.1 | 20 |
| 91 | Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. <i>Clinical Therapeutics</i> , 2018 , 40, 952-962.e2 | 3.5 | 16 |
| 90 | The European organization for research and treatment of cancer - satisfaction with cancer care questionnaire: revision and extended application development. <i>Psycho-Oncology</i> , 2017 , 26, 400-404 | 3.9 | 9 |
| 89 | Optimized Outcomes Using a Standardized Approach for the Treatment of Patients with Carcinoid Heart Disease. <i>Neuroendocrinology</i> , 2017 , 104, 257-263 | 5.6 | 5 |
| 88 | ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2017 , 105, 255-265 | 5.6 | 136 |
| 87 | ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. <i>Neuroendocrinology</i> , 2017 , 105, 295-309 | 5.6 | 142 |
| 86 | A Systematic Review of Symptoms and Quality of Life Issues in Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2017 , 105, 320-330 | 5.6 | 4 |
| 85 | Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. <i>Clinical Therapeutics</i> , 2017 , 39, 2158-2168 | 3.5 | 32 |
| 84 | Tumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumours. <i>Endocrine Connections</i> , 2017 , 6, 876-885 | 3.5 | 8 |
| 83 | Acute Liver Failure in a Patient Travelling From Asia: The Other Face of the Coin of Infectious Disease. <i>Gastroenterology Research</i> , 2017 , 10, 268-270 | 1.8 | |

| | | | |
|----|--|------|-----|
| 82 | Neuroendocrine Tumors. <i>Gastroenterology Clinics of North America</i> , 2016 , 45, 487-507 | 4.4 | 22 |
| 81 | ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2016 , 103, 139-43 | 5.6 | 153 |
| 80 | ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2016 , 103, 119-24 | 5.6 | 258 |
| 79 | The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. <i>Hepatology</i> , 2016 , 63, 930-50 | 11.2 | 184 |
| 78 | How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist. <i>European Journal of Gastroenterology and Hepatology</i> , 2016 , 28, 146-52 | 2.2 | 24 |
| 77 | Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder. <i>British Journal of Cancer</i> , 2016 , 115, 1032-1038 | 8.7 | 17 |
| 76 | Review article: the investigation and management of rectal neuroendocrine tumours. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 332-45 | 6.1 | 50 |
| 75 | International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. <i>Nature Communications</i> , 2015 , 6, 8019 | 17.4 | 185 |
| 74 | Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 1511-9 | 5.6 | 84 |
| 73 | Letter: the response to somatostatin analogues in neuroendocrine tumours is influenced by Ki67 score--authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 1034-5 | 6.1 | |
| 72 | Personalized medicine for gastroenteropancreatic neuroendocrine tumors: a distant dream?. <i>International Journal of Endocrine Oncology</i> , 2015 , 2, 201-215 | 0.3 | 1 |
| 71 | Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 5075-86 | 4.4 | 139 |
| 70 | Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. <i>Annals of Oncology</i> , 2015 , 26, 1604-20 | 10.3 | 363 |
| 69 | Review article: the investigation and management of gastric neuroendocrine tumours. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1071-84 | 6.1 | 72 |
| 68 | ENETS TNM Staging Predicts Prognosis in Small Bowel Neuroendocrine Tumours. <i>ISRN Oncology</i> , 2013 , 2013, 420795 | | 17 |
| 67 | Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. <i>British Journal of Cancer</i> , 2013 , 108, 301-10 | 8.7 | 68 |
| 66 | GLP-1 and glucagon secretion from a pancreatic neuroendocrine tumor causing diabetes and hyperinsulinemic hypoglycemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 3039-45 | 5.6 | 16 |
| 65 | Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). <i>Gut</i> , 2012 , 61, 6-32 | 19.2 | 522 |

| | | | |
|----|---|------|-----|
| 64 | A multimodal approach to the management of neuroendocrine tumour liver metastases. <i>International Journal of Hepatology</i> , 2012 , 2012, 819193 | 2.7 | 25 |
| 63 | Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21. <i>British Journal of Cancer</i> , 2011 , 104, 587-92 | 8.7 | 20 |
| 62 | Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. <i>Gut</i> , 2010 , 59, 1245-51 | 19.2 | 212 |
| 61 | ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. <i>Neuroendocrinology</i> , 2010 , 91, 341-50 | 5.6 | 51 |
| 60 | Carcinoid syndrome. <i>BMJ, The</i> , 2010 , 341, c3941 | 5.9 | 7 |
| 59 | Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. <i>Endocrine-Related Cancer</i> , 2009 , 16, 885-94 | 5.7 | 202 |
| 58 | Validation of the European Organization for Research and Treatment of Cancer QLQ-LMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases. <i>British Journal of Surgery</i> , 2009 , 96, 291-8 | 5.3 | 42 |
| 57 | Differential item functioning (DIF) in the EORTC QLQ-C30: a comparison of baseline, on-treatment and off-treatment data. <i>Quality of Life Research</i> , 2009 , 18, 381-8 | 3.7 | 29 |
| 56 | Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. <i>Neuroendocrinology</i> , 2008 , 87, 40-6 | 5.6 | 60 |
| 55 | Consensus guidelines for the management of patients with digestive neuroendocrine tumors--well-differentiated jejunal-ileal tumor/carcinoma. <i>Neuroendocrinology</i> , 2008 , 87, 8-19 | 5.6 | 198 |
| 54 | Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. <i>Neuroendocrinology</i> , 2008 , 87, 31-9 | 5.6 | 90 |
| 53 | Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. <i>Neuroendocrinology</i> , 2008 , 87, 47-62 | 5.6 | 240 |
| 52 | Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. <i>Neuroendocrinology</i> , 2008 , 87, 20-30 | 5.6 | 95 |
| 51 | Reply to the Letter by Scher on Well-Differentiated Neuroendocrine Tumours of Colon and Rectum. <i>Neuroendocrinology</i> , 2008 , 88, 158-159 | 5.6 | |
| 50 | Translation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approach. <i>European Journal of Cancer</i> , 2007 , 43, 1810-20 | 7.5 | 177 |
| 49 | Gastrinoma (duodenal and pancreatic). <i>Neuroendocrinology</i> , 2006 , 84, 173-82 | 5.6 | 216 |
| 48 | Well-differentiated gastric tumors/carcinomas. <i>Neuroendocrinology</i> , 2006 , 84, 158-64 | 5.6 | 113 |
| 47 | Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas). <i>Neuroendocrinology</i> , 2006 , 84, 165-72 | 5.6 | 56 |

| | | | |
|----|---|------|------|
| 46 | Well-differentiated pancreatic nonfunctioning tumors/carcinoma. <i>Neuroendocrinology</i> , 2006 , 84, 196-211 | 5.6 | 206 |
| 45 | Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). <i>Neuroendocrinology</i> , 2006 , 84, 212-5 | 5.6 | 86 |
| 44 | Well-differentiated pancreatic tumor/carcinoma: insulinoma. <i>Neuroendocrinology</i> , 2006 , 84, 183-8 | 5.6 | 191 |
| 43 | Rare functioning pancreatic endocrine tumors. <i>Neuroendocrinology</i> , 2006 , 84, 189-95 | 5.6 | 104 |
| 42 | Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours. <i>European Journal of Cancer</i> , 2006 , 42, 477-84 | 7.5 | 57 |
| 41 | Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 1087-97 | 6.1 | 69 |
| 40 | TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006 , 449, 395-401 | 5.1 | 1185 |
| 39 | Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. <i>Gut</i> , 2005 , 54 Suppl 4, iv1-16 | 19.2 | 241 |
| 38 | Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2005 , 17, 739-44 | 2.2 | 38 |
| 37 | Tumeurs carcinoïdes de l'intestin grêle. <i>Acta Endoscopica</i> , 2005 , 35, 187-193 | | |
| 36 | Neuroendocrine tumour management: a team approach. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2005 , 66, 37-42 | 0.8 | 7 |
| 35 | Are renal microgranulomas related to inflammatory tubular destruction?. <i>Journal of Clinical Pathology</i> , 2004 , 57, 551-2 | 3.9 | 5 |
| 34 | Management of neuroendocrine liver metastases. <i>American Journal of Surgery</i> , 2004 , 187, 39-46 | 2.7 | 112 |
| 33 | Proliferation of antigen MIB-1 in metastatic carcinoid tumours removed at liver transplantation: relevance to prognosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2003 , 15, 139-43 | 2.2 | 28 |
| 32 | Measurement of quality of life in carcinoid/neuroendocrine tumours. <i>Endocrine-Related Cancer</i> , 2003 , 10, 483-6 | 5.7 | 16 |
| 31 | Churg-Strauss syndrome and granulomatous cholangiopathy. <i>European Journal of Gastroenterology and Hepatology</i> , 2000 , 12, 809-11 | 2.2 | 7 |
| 30 | Clinical features, diagnosis and outcome of acute portal vein thrombosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2000 , 93, 531-4 | 2.7 | 84 |
| 29 | The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipients. <i>Journal of Hepatology</i> , 1997 , 27, 1015-21 | 13.4 | 36 |

| | | | |
|----|---|------|-----|
| 28 | A treatable cause of lymphocytic meningo-encephalitis. <i>Postgraduate Medical Journal</i> , 1997 , 73, 437-8 | 2 | 1 |
| 27 | Imaging secondary neuroendocrine tumours of the liver: comparison of I123 metaiodobenzylguanidine (MIBG) and In111-labelled octreotide (Octreoscan). <i>QJM - Monthly Journal of the Association of Physicians</i> , 1996 , 89, 539-42 | 2.7 | 15 |
| 26 | p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. <i>Gut</i> , 1996 , 38, 265-8 | 19.2 | 41 |
| 25 | Hepatic venous outflow obstruction in patients with polycystic liver disease: pathogenesis and treatment. <i>Gut</i> , 1995 , 36, 142-5 | 19.2 | 55 |
| 24 | Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. <i>Gastroenterology</i> , 1995 , 108, 865-9 | 13.3 | 209 |
| 23 | Overview: the management of metastatic carcinoid tumors. <i>Liver Transplantation</i> , 1995 , 1, 107-10 | | 10 |
| 22 | Orthotopic liver transplantation in the treatment of metastatic neuroendocrine tumors of the liver. <i>Liver Transplantation</i> , 1995 , 1, 118-21 | | 49 |
| 21 | Ribavirin therapy for hepatitis C infection following liver transplantation. <i>Transplant International</i> , 1995 , 8, 61-4 | 3 | 14 |
| 20 | Nodular regenerative hyperplasia of the liver graft after liver transplantation. <i>Hepatology</i> , 1994 , 20, 88-94 | 11.2 | 88 |
| 19 | FK 506 rescue therapy for intractable liver allograft rejection. <i>Transplant International</i> , 1994 , 7 Suppl 1, S70-6 | 3 | 5 |
| 18 | Parvovirus B19-induced red cell aplasia treated with plasmapheresis and immunoglobulin. <i>Lancet, The</i> , 1994 , 343, 667-8 | 4.0 | 27 |
| 17 | Effect of region, temperature and neuronal blockade on sodium and 51Cr-EDTA transport across canine gastrointestinal mucosae in vitro. <i>Comparative Biochemistry and Physiology A, Comparative Physiology</i> , 1994 , 107, 711-7 | | 4 |
| 16 | Accuracy of radiology in detection of hepatocellular carcinoma before liver transplantation. <i>Gastroenterology</i> , 1994 , 107, 1425-9 | 13.3 | 69 |
| 15 | Nodular regenerative hyperplasia of the liver graft after liver transplantation. <i>Hepatology</i> , 1994 , 20, 88-94 | 11.2 | 12 |
| 14 | Randomised trial of variceal banding ligation versus injection sclerotherapy for bleeding oesophageal varices. <i>Lancet, The</i> , 1993 , 342, 391-4 | 4.0 | 255 |
| 13 | Antigen-induced mucosal damage and restitution in the small intestine of the immunized rat. <i>International Archives of Allergy and Immunology</i> , 1990 , 91, 270-7 | 3.7 | 24 |
| 12 | Acute diarrhoea in expatriates in Bangladesh. <i>Gut</i> , 1990 , 31, 123 | 19.2 | |
| 11 | Intestinal mucosal injury is associated with mast cell activation and leukotriene generation during Nippostrongylus-induced inflammation in the rat. <i>Digestive Diseases and Sciences</i> , 1989 , 34, 724-31 | 4 | 62 |

| | | | |
|----|---|------|----|
| 10 | Changes in intestinal permeability and epithelial differentiation during inflammation in the rat. <i>Gut</i> , 1988 , 29, 57-61 | 19.2 | 36 |
| 9 | Effect of immunologic reactions on rat intestinal epithelium. <i>Gastroenterology</i> , 1988 , 94, 1368-1375 | 13.3 | 77 |
| 8 | Effect of immunologic reactions on rat intestinal epithelium. Correlation of increased permeability to chromium 51-labeled ethylenediaminetetraacetic acid and ovalbumin during acute inflammation and anaphylaxis. <i>Gastroenterology</i> , 1988 , 94, 1368-75 | 13.3 | 19 |
| 7 | Large single daily dose of histamine H2 receptor antagonist for duodenal ulcer. How much and when? A clinical pharmacological study. <i>Gut</i> , 1987 , 28, 566-72 | 19.2 | 21 |
| 6 | Barrett's oesophagus. <i>Lancet, The</i> , 1987 , 2, 851 | 40 | 7 |
| 5 | Effect of enprostil, a synthetic prostaglandin E2 on 24 hour intragastric acidity, nocturnal acid and pepsin secretion. <i>Gut</i> , 1986 , 27, 1054-7 | 19.2 | 14 |
| 4 | Effect of cimetidine and pirenzepine in combination on 24 hour intragastric acidity in subjects with previous duodenal ulceration. <i>Gut</i> , 1986 , 27, 428-32 | 19.2 | 13 |
| 3 | Inhibition of food stimulated acid secretion by misoprostol, an orally active synthetic E1 analogue prostaglandin. <i>British Journal of Clinical Pharmacology</i> , 1985 , 19, 9-12 | 3.8 | 11 |
| 2 | Smoking, gastric secretion, and inhibition by H2 receptor antagonists. <i>Lancet, The</i> , 1985 , 1, 1049 | 40 | 3 |
| 1 | Ranitidine 150 mg twice daily vs 300 mg nightly in treatment of duodenal ulcers. <i>Lancet, The</i> , 1984 , 2, 274-6 | 40 | 93 |